chrX-150614694-TGTAAA-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000252.3(MTM1):c.342_342+4delAGTAA(p.Asp115fs) variant causes a frameshift, splice donor, splice region, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000252.3 frameshift, splice_donor, splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MTM1 | NM_000252.3 | c.342_342+4delAGTAA | p.Asp115fs | frameshift_variant, splice_donor_variant, splice_region_variant, intron_variant | Exon 5 of 15 | ENST00000370396.7 | NP_000243.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 22
GnomAD4 genome Cov.: 22
ClinVar
Submissions by phenotype
Severe X-linked myotubular myopathy Pathogenic:5
- -
- -
- -
This variant results in the deletion of part of exon 5 (c.342_342+4del) of the MTM1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MTM1 are known to be pathogenic (PMID: 9305655, 10063835). This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with X-linked myotubular myopathy (PMID: 9285787, 29567349). This variant is also known as delta392-396GTAAA. ClinVar contains an entry for this variant (Variation ID: 211532). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
This variant affects the canonical splice donor site of intron 5 and is therefore predicted to interfere with splicing and result in loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay (NMD). This variant has been previously reported as a hemizygous change, named as c.338-342delGTAAA, in a male individual with a severe myotubular myopathy (PMID: 10790201). This alteration was also identified in a female carrier with a progressive myopathic weakness (PMID: 29567349). It is absent from the gnomAD population database and thus is presumed to be rare. Based on the available evidence, the c.342_342+4del variant is classified as Pathogenic. -
not provided Pathogenic:2
The variant results in a shift of the reading frame, and is therefore predicted to result in the loss of a functional protein. Found in at least one symptomatic patient, and not found in general population data. -
The c.342_342+4delAGTAA pathogenic variant in the MTM1 gene has been reported previously in a male individual with myotubular myopathy (Laporte et al., 2000). This deletion spans the splice junction and destroys the canonical splice donor site in intron 5. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. The c.342_342+4delAGTAA variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret c.342_342+4delAGTAA as a pathogenic variant. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at